Ansal Buildwell is a real estate developer that builds residential townships, commercial complexes, and hospitality projects primarily in Northern India, earning revenue through property sales and club memberships.
The company lacks a durable competitive advantage, as evidenced by negative revenue and EPS growth over time. While it has a portfolio of townships, it lacks pricing power or cost advantages, and its ROCE of 8.7% is below the typical cost of capital for the sector.
Capital allocation is poor, characterized by declining earnings and capital tied up in stalled or legally disputed projects. The company recently paid over 21 crore INR to settle a subsidiary's debt to prevent a corporate guarantee invocation, indicating significant leakage to support failing ventures.
The company's demise was driven by the 'bleeding parent' syndrome, where the core business was hollowed out to cover the insolvency of subsidiaries like Ansal Crown Infrabuild. As legal disputes in Gwalior and Faridabad remained unresolved, capital stayed trapped in non-productive assets while interest coverage continued to erode. The combination of negative revenue growth and high promoter remuneration eventually exhausted the remaining liquidity, leading to a total collapse of shareholder equity as contingent liabilities were crystallized by court orders.
RichFakir rates Ansal Buildwell Ltd's business quality as poor — 11/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Ansal Buildwell Ltd is trading about 34% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Ansal Buildwell Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Ansal Buildwell Ltd's fair value is about ₹54 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →